血清CEA、CA125、D-二聚体联合检测在卵巢癌临床诊断中的价值分析  

Clinical Value of Combined Serum CEA,CA125,and D-Dimer Testing in Ovarian Cancer Diagnosis

作　　者：刘秀艳 云雨 史硕达 李守山[1] 位振 LIU Xiu-yan;YUN Yu;SHI Shuo-da;LI Shou-shan;WEI Zhen(Siyang County Hospital of Traditional Chinese Medicine,Suqian,223700,Jiangsu)

机构地区：[1]泗阳县中医院,江苏宿迁223700

出　　处：《黔南民族医专学报》2024年第4期387-391,共5页Journal of Qiannan Medical College for Nationalities

基　　金：宿迁市中医药科技项目(YB202209)。

摘　　要：目的:分析血清癌胚抗原(CEA)、糖类抗原125(CA125)、D-二聚体(D-D)联合检测在卵巢癌临床诊断中的应用价值。方法:选取在本院确诊的卵巢癌患者及卵巢良性病变患者各67例,分别列为恶性组和良性组,另选取同期本院健康女性体检者67例为正常对照组。比较三组血清CEA、CA125、D-D水平及三项血清指标的阳性表达情况,并比较三项血清指标单独及联合检测对卵巢癌的诊断效能。结果:相较于正常对照组,恶性组、良性组血清CEA、CA125、D-D水平均明显上升(P<0.05);相较于良性组,恶性组三项血清指标水平均明显上升(P<0.05);相较于正常对照组,恶性组、良性组三项血清指标单独及联合检测阳性检出率均明显升高(P<0.05);相较于良性组,恶性组三项血清指标单独及联合检测阳性检出率均明显升高(P<0.05)。血清CEA、CA125、D-D单独及联合检测的AUCROC分别为0.836(95%CI:0.767~0.904)、0.860(95%CI:0.798~0.923)、0.950(95%CI:0.905~0.994)、0.995(95%CI:0.000~1.000),三项血清指标联合检测的AUCROC最大,对卵巢癌的诊断效能最高。结论:CEA、CA125、D-D在卵巢癌患者血清中明显升高,通过联合检测血清中的CEA、CA125、D-D,可显著提高卵巢癌的诊断准确性,利于临床早期发现及治疗卵巢癌,从而改善患者预后,延长患者的生存期。Objective:This study aims to evaluate the application value of combined serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and D-dimer(D-D)detection in the clinical diagnosis of ovarian cancer.Methods:A total of 67 patients with pathologically confirmed ovarian cancer and 67 patients with benign ovarian lesions from our hospital were selected as the malignant group and benign group,respectively.Additionally,67 healthy female subjects who underwent physical examinations at our hospital during the same period were chosen as the normal control group.Serum levels of CEA,CA125,and D-D were measured and compared among the three groups.The positive expression rates of these three serum markers were also evaluated individually and in combination for their diagnostic efficiency in ovarian cancer.Results:Compared to the normal control group,serum levels of CEA,CA125,and D-D were significantly higher in both the malignant and benign groups(P<0.05).Moreover,the levels of all three serum markers were significantly higher in the malignant group compared to the benign group(P<0.05).The positive detection rates for individual and combined testing of the three serum markers were significantly higher in both the malignant and benign groups compared to the normal control group(P<0.05),and significantly higher in the malignant group compared to the benign group(P<0.05).The area under the receiver operating characteristic curve(AUCROC)for CEA,CA125,D-D,and the combined test were 0.836(95%CI:0.767-0.904),0.860(95%CI:0.798-0.923),0.950(95%CI:0.905-0.994),and 0.995(95%CI:0.000-1.000),respectively.The combined detection of the three serum markers had the largest AUCROC,indicating the highest diagnostic efficiency for ovarian cancer.Conclusion:Serum levels of CEA,CA125,and D-D are significantly elevated in patients with ovarian cancer.Combined detection of these markers can significantly improve the accuracy of diagnosing ovarian cancer,aiding in early detection and treatment,thereby improving patient prognosis and extend

关 键 词：血清CEA CA125 D-二聚体 卵巢癌 临床诊断 

分 类 号：R737.31[医药卫生—肿瘤]